Neuropsychology Abstract of the Day: Alzheimer's Disease
GOOD or BAD responder? Behavioural and neuroanatomical markers of clinical response to donepezil in dementia.Behav Neurol. 2012;25(2):61-72 Authors: Bottini G, Berlingeri M, Basilico S, Passoni S, Danelli L, Colombo N, Sberna M, Franceschi M, Sterzi R, Paulesu E
Abstract
We explored the neuropsychological and neuromorphometrical differences between probable Alzheimer's disease patients showing a good or a bad response to nine months treatment with donepezil. Before treatment, the neuropsychological profile of the two patient groups was perfectly matched. By the ninth month after treatment, the BAD-responders showed a decline of the MMSE score together with a progressive impairment of executive functions. A voxel-based morphometry investigation (VBM), at the time of the second neuropsychological assessment, showed that the BAD-responders had larger grey and white matter atrophies involving the substantia innominata of Meynert bilaterally, the ventral part of caudate nuclei and the left uncinate fasciculus, brain areas belonging to the cholinergic pathways. A more widespread degeneration of the central cholinergic pathways may explain the lack of donepezil efficacy in those patients not responding to a treatment that operates on the grounds that some degree of endogeneous release of acetylcholine is still available.
PMID: 22530263 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Donepezil, Mci, And Ad
Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL & Alzheimer's Disease Cooperative Study Group. (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 72(24):, 2115-2121. Departments of Neurology,...
- Neuropsychology Abstract Of The Day: Alzheimer Drug Regimens & Delivery Systems
Bassil, N & Grossberg, GT. (2009). Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs, 23(4), 293-307. The mainstay of current management of patients with Alzheimer's disease involves drugs that...
- Neuropsychology Abstract Of The Day: Agitation In Alzheimer's Disease (ad)
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation...
- Abstract Of The Day: Alzheimer Disease Drug Treatments
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD005593. BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients...
- Donepezil, Vitamin E, And Mild Cognitive Impairment In Aging
The New England Journal of Medicine has made available on its website prepublication versions of the results of a large study relevant to aging, neuropsychological changes in aging, and the onset of dementia. It has also made available in the same format...